

Pan-Ming Jian,<sup>a</sup> Yi-Zhi Li,<sup>b</sup>  
Xiao-Li Wu,<sup>a</sup> Yong-Xiang Ma,<sup>a\*</sup>  
Da-Hua Pan<sup>a</sup> and Bao-Hua  
Chen<sup>a</sup><sup>a</sup>National Laboratory of Applied Organic  
Chemistry, Lanzhou University, Lanzhou  
730000, People's Republic of China, and  
<sup>b</sup>Coordination Chemistry Institute, State Key  
Laboratory of Coordination Chemistry, Nanjing  
University, Nanjing 210093, People's Republic  
of China

Correspondence e-mail: llyjz@nju.edu.cn

## Key indicators


Single-crystal X-ray study  
T = 293 K  
Mean  $\sigma(C-C)$  = 0.003 Å  
R factor = 0.034  
wR factor = 0.092  
Data-to-parameter ratio = 11.6For details of how these key indicators were  
automatically derived from the article, see  
<http://journals.iucr.org/e>.1-[(5-Chloro-2-hydroxyphenyl)(phenyl)-  
methyl]-2-(2-pyridyl)-1H-benzimidazoleThe title compound, C<sub>25</sub>H<sub>18</sub>ClN<sub>3</sub>O, results from the intramolecular reaction of a difunctional Schiff base in the presence of acid as a catalyst. There is a chiral C atom in the molecule, but the crystal structure is a racemic mixture. There is one strong intermolecular O—H···N hydrogen bond and three weak C—H···N interactions (two intra- and one intermolecular), leading to the formation of a helical chain of molecules.

Received 14 April 2003

Accepted 6 May 2003


Online 16 May 2003

## Comment


The preparation of benzimidazoles has attracted some attention due to their varied physiological characteristics, such as anticancer agents, fungicides, antichagasic drugs, inhibitors, and plant-growth regulators (Zhou & Hassner, 2001; Matsuno *et al.*, 2000; Kucukbay *et al.*, 2001; Purygin *et al.*, 2000; Bag *et al.*, 1996).In general, benzimidazole derivatives are obtained by the reaction of an *o*-phenylenediamine with a carboxylic acid, ester, amide, nitrile *etc.*, or by the palladium-catalysed carbonylation, coupling and cyclization of haloaromatics and *o*-phenylenediamines. Recently, Alajarin *et al.* (1999) described a [4 + 2] intramolecular cycloaddition of ketimines with imines to form benzimidazo[1,2-*b*]isoquinolines, but it is a tedious procedure requiring expensive reagents. This paper reports a novel method for the synthesis of 1,2-benzimidazoles in good yields, by hydrogen-transfer cyclization between azomethine groups in the presence of acidic catalysts under mild conditions.There is a chiral C atom in the molecule of the title compound, (II); however, it crystallizes as a racemic mixture in the centrosymmetric space group *P* 2<sub>1</sub>/*c*. The dihedral angle between the benzimidazole ring system and the pyridyl ring is 24.29 (8)°. The bond angles H13—C13—N2, H13—C13—C20 and H13—C13—C14 are 103.2 (8), 110.0 (8) and 105.7 (8)°, respectively. There is one strong intermolecular O—H···N hydrogen bond and three weak C—H···N interactions (two intra- and one intermolecular), leading to the formation of a helical chain of molecules (Fig. 3).

## Experimental


The title compound, (II), was prepared as follows: in the presence of *p*-CH<sub>3</sub>C<sub>6</sub>H<sub>4</sub>SO<sub>3</sub>H, an intramolecular hydrogen-transfer cyclization of 1-*N*-(phenyl-5-chloro-2-hydroxyphenyl)methylene-2-*N*-(pyridin-2-



**Figure 1**  
The molecular structure of title compound, with ellipsoids drawn at the 50% probability level.



**Figure 2**  
The packing of the title compound, viewed down the *b* axis.



**Figure 3**  
The crystal packing, showing the intermolecular interactions leading to the formation of two helical chains.

yl)methylene-1,2-phenylenedimine was carried out between the two C=N bonds of the asymmetrical difunctional Schiff base (I) to give cyclozation product (II). The hydrogen on the C atom of the aldimine transferred to the C atom of the ketoimine and formed a chiral center. The specific rotation of the product is zero, as it is racemic. A single crystal of the title compound was obtained by slow diffusion (1:1 MeOH–MeCN) over a period of one month.

#### Crystal data

$C_{25}H_{18}ClN_3O$   
 $M_r = 411.87$   
Monoclinic,  $P2_1/c$   
 $a = 13.515 (2) \text{ \AA}$   
 $b = 9.597 (2) \text{ \AA}$   
 $c = 16.875 (2) \text{ \AA}$   
 $\beta = 110.01 (1)^\circ$   
 $V = 2056.6 (6) \text{ \AA}^3$   
 $Z = 4$

$D_x = 1.330 \text{ Mg m}^{-3}$   
Mo  $K\alpha$  radiation  
Cell parameters from 25 reflections  
 $\theta = 2.1\text{--}23.2^\circ$   
 $\mu = 0.21 \text{ mm}^{-1}$   
 $T = 293 (2) \text{ K}$   
Block, colorless  
 $0.3 \times 0.2 \times 0.2 \text{ mm}$

#### Data collection

Bruker P4 diffractometer  
 $\omega$  scans  
Absorption correction:  $\psi$  scan  
(*XPRED* in *SHELXTL*; Bruker, 2000)  
 $T_{\min} = 0.95$ ,  $T_{\max} = 0.96$   
10228 measured reflections  
3982 independent reflections  
3129 reflections with  $I > 2\sigma(I)$

$R_{\text{int}} = 0.045$   
 $\theta_{\text{max}} = 26.0^\circ$   
 $h = -16 \rightarrow 16$   
 $k = -11 \rightarrow 11$   
 $l = -19 \rightarrow 19$   
3 standard reflections  
every 97 reflections  
intensity decay: none

#### Refinement

Refinement on  $F^2$   
 $R[F^2 > 2\sigma(F^2)] = 0.034$   
 $wR(F^2) = 0.092$   
 $S = 1.01$   
3982 reflections  
343 parameters

All H-atom parameters refined  
 $w = 1/[\sigma^2(F_o^2) + (0.02P)^2]$   
where  $P = (F_o^2 + 2F_c^2)/3$   
 $(\Delta/\sigma)_{\text{max}} < 0.001$   
 $\Delta\rho_{\text{max}} = 0.20 \text{ e \AA}^{-3}$   
 $\Delta\rho_{\text{min}} = -0.15 \text{ e \AA}^{-3}$

**Table 1**

Selected geometric parameters ( $\text{\AA}$ ,  $^\circ$ ).

N2—C13	1.4802 (16)	C20—C13	1.5251 (18)
C14—C13	1.5109 (19)	C13—H13	0.952 (13)
N2—C13—C14	112.56 (11)	N2—C13—H13	103.2 (8)
N2—C13—C20	110.27 (10)	C14—C13—H13	105.7 (8)
C14—C13—C20	114.47 (11)	C20—C13—H13	110.0 (8)

**Table 2**

Hydrogen-bonding geometry ( $\text{\AA}$ ,  $^\circ$ ).

<i>D</i> —H... <i>A</i>	<i>D</i> —H	H... <i>A</i>	<i>D</i> ... <i>A</i>	<i>D</i> —H... <i>A</i>
O1—H1 <sup>i</sup> ...N1 <sup>i</sup>	0.99 (2)	1.77 (2)	2.7520 (16)	174.8 (17)
C13—H13...N3	0.952 (13)	2.317 (13)	2.9422 (19)	122.6 (9)
C15—H15...N2	1.005 (15)	2.513 (15)	2.8643 (19)	100.0 (10)
C23—H23...N1 <sup>ii</sup>	0.977 (19)	2.568 (19)	3.464 (2)	152.5 (14)

Symmetry codes: (i)  $1 - x, \frac{1}{2} + y, \frac{1}{2} - z$ ; (ii)  $x, 1 + y, z$ .

All H atoms were found in difference maps and refined isotropically. C—H bond lengths are in the range 0.952 (13)–1.058 (15)  $\text{\AA}$ . The O—H bond length is 0.99 (2)  $\text{\AA}$ .

Data collection: *XSCANS* (Bruker, 2000); cell refinement: *XSCANS*; data reduction: *XSCANS*; program(s) used to solve structure: *SHELXTL* (Bruker, 2000); program(s) used to refine structure: *SHELXTL*; molecular graphics: *SHELXTL*; software used to prepare material for publication: *SHELXTL*.

This work was supported by the Natural Science Foundation (QT program) of the PRC and the Natural Science Foundation of Gansu Province of China (YS991-A25-001).

## References

- Alajarin, M., Vidal, A. Tovar, F. & Conesa, C. (1999). *Tetrahedron Lett.* **40**, 6127–6130.
- Bag, S. K., Chakraborty, S. B. & Chaudhuri, S. R. (1996). *J. Ind. Chem. Soc.* **73**, 113–118.
- Bruker (2000). XSCANS and SHELXTL. Bruker AXS Inc., Madison, Wisconsin, USA.
- Kucukbay, H., Durmaz, R., Guven, M. & Gunal, S. (2001). *Arznein. Forsch.* **51**, 420–424.
- Matsuno, T., Kato, M., Sasahara, H., Watanabe, T., Inaba, M., Takahashi, M., Yaguchi, S., Yoshioka, K., Sakato, M. & Kawashima, S. (2000). *Chem. Pharm. Bull.* **48**, 1778–1781.
- Purygin, P. P., Kuz'mina, V. E., Sergeeva, L. I., Pan'kov, S. V., Belyakova, N. A. & Zarubin, Yu. P. (2000). *Pharm. Chem. J.* **34**, 53–55.
- Zhou, C. & Hassner, A. (2001). *Carbohydr. Res.* **333**, 313–326.